Increasing HAART-Induced Immune Restoration With Cyclosporine
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if cyclosporine, taken when a patient begins highly
active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that
fight infection) in a patient's blood. This study also will explore the safety of briefly
giving cyclosporine to patients starting HAART.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)